Did You Know?

Editor’s Picks

Latest News

Nephrolytics Closes $2.5M SAFE Round, Launches Saya™ First Full Stack Agentic Solution for Kidney Disease Care, and Showcases Breakthrough at RPA 2025

CHUBBUCK, Idaho, June 25, 2025 /PRNewswire/ -- Nephrolytics, Inc., the AI-powered clinical intelligence platform revolutionizing kidney care, today announced three...

Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Platinum-Resistant Ovarian Cancer

GUANGZHOU, China, June 25, 2025 /PRNewswire/ - Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and...

Slide Stainers Market to Reach $5.53 Billion by 2032, Growing at a CAGR of 7.9% from 2025, Says Meticulous Research®

Market Growth Driven by Rising Geriatric Population, Chronic Disease Burden, Laboratory Automation Demand, and Advanced Diagnostic Technology Integration REDDING, Calif.,...

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) --...

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa’s Strategic Focus on Ovarian Cancer and Autoimmune Disease ProgramsCAMBRIDGE,...

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement...

error: Content is protected !!